Capecitabine CAS 154361-50-9 Munditia 98.0%~ 102.0% API Quality
Commercial Supple Capecitabine Related Intermedia:
5-Fluorocytosine CAS: 2022-85-7
2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidinis CAS: 161599-46-8
1,2,3 Tri-O-acetyl-5-deoxy-β-D-ribofuranosum CAS: 62211-93-2
Capecitabine CAS: 154361-50-9
| Nomen chemicum | Capecitabine |
| CAS Number | 154361-50-9 |
| CATTUS Number | RF-API08 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C15H22FN3O6 |
| M. Pondus | 359.35 |
| Liquescens punctum | 110.0~121.0℃ |
| Shipping Condition | Sub Ambient Temperature |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba pulveris |
| Lepidium sativum | IR Spectrum specimen debet concordare cum spectro relationis vexillum |
| Lepidium sativum | HPLC: Retentionis tempus solutionis maioris cacuminis sample solutionis congruenti respondere debet vexillum relationis. |
| Puritas | 98.0% ~ 102.0% (in anhydrous et solvendo-liber basis) |
| Optical gyrationis | +96.0°~+100° |
| Humor (KF) | ≤0.30% |
| Reliqua ignitio | ≤0.10% |
| Metalla gravis | ≤20ppm |
| Related immunditiam A | ≤0.30% |
| Related immunditiam B | ≤0.30% |
| Related immunditiam C | ≤0.10% (2',3'-Di O-Acety-5'-deoxy-5-Fluoroytidine) |
| Impuritas una non specificata | ≤0.10% |
| Totalis non specificatae immunditias | ≤0.50% |
| Totalis immunditias | ≤1.5% |
| RELICTUM Solvents (GC) | |
| Methanol | ≤3000ppm |
| Ethanol | ≤5000ppm |
| Dichloromethane | ≤600ppm |
| Ethyl Acetate | ≤5000ppm |
| Toluene | ≤800ppm |
| Pyridine | ≤200ppm |
| Hexane | ≤290ppm |
| Summa Aerobic Microbial comitis | ≤200cfc/g |
| Fermenta et fingit comes | ≤50cfc/g |
| Test Standard | Pharmacopoeia Civitatum Foederatarum (USP) |
| Consuetudinem | Pectus Cancer metastatic |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Capecitabine (CAS: 154361-50-9) est nova forma medicamenti pyrimidinis oris fluorinated.Capecitabinum a Roche Pharmaceuticis explicatum est, et nomen eius mercatorum Xeloda est.Capecitabinum vivo in 5. FU mutare potest, medicamentum anti-metabolizim fluorinum pyrimidinem deoxynucleoside carbamatum, qui scuta cellas cancri ad divisionem cellam inhibent et RNA et interdum synthesim perturbant.Effectus eius signanter ligantur cum plano TP enzyme expressionis in textu neoplastico et DPD enzyme in expressione vivo.Idoneum est curationi ulteriori provectioris primae vel metastaticae cancer pectoris aegros qui paclitaxel vel anthracyclinis antibioticis non responderunt.Ut anticancer medicamento, plerumque tractare cancrum pectus primarium vel metastaticum provectus est, tum in curatione de cancro cellulae pulmone non parva, cancer pancreaticus, cancer vesicae, cancer rectalis, cancer colon, cancer gastricus, et alii tumores solidi. .
